![]() |
市场调查报告书
商品编码
1388287
综合代谢面板测试市场 - 按测试类型(葡萄糖、钙、电解质、肾功能测试、肝功能测试、蛋白质)、按疾病适应症(肾臟疾病)Comprehensive Metabolic Panel Testing Market - By Test Type (Glucose, Calcium, Electrolytes, Kidney Function Tests, Liver Function Tests, Proteins), By Disease Indication (Kidney Diseases) |
由于慢性病盛行率不断上升、人口老化以及对代谢紊乱早期检测和监测的需求日益增加,综合代谢检测市场规模预计从 2023 年到 2032 年将以 8.7% 的复合CAGR扩大。
人们对预防保健意识的不断增强和诊断技术的不断进步正在推动综合代谢组在常规健康检查中的整合。例如,2022 年 1 月,Quest Diagnostics 透过 QuestDirect (TM) 推出了虚拟预防护理服务,使个人能够主动管理自己的健康和福祉。对个人化医疗的需求激增以及床边检测的广泛采用将进一步扩大市场成长,以满足不同患者群体不断变化的医疗保健需求。
综合代谢组测试产业分为测试类型、疾病适应症、最终用途和地区。
根据测试类型,由于肾臟疾病盛行率不断增加,预计到 2032 年,肾功能测试领域的市占率复合CAGR将达到 8.6%。人口老化的加剧以及肾功能测试在评估和监测肾臟健康方面的关键作用将促进该领域的成长。
肝病适应症领域预计将在综合代谢组测试市场中占据相当大的份额,2023 年至 2032 年CAGR为 8.5%。肝臟疾病的盛行率日益增加,促使早期检测的需求不断增加。代谢组在评估肝功能中的关键作用也将推动该细分市场的扩张。
就最终用途而言,医院细分市场的市场价值预计在 2023 年至 2032 年期间保持 8.5% 的CAGR。这是由于医院患者数量庞大以及对快速诊断服务的需求不断增长所推动的。此外,将代谢组常规纳入综合医疗保健评估中将刺激医院环境中的检测需求。
从区域来看,由于代谢紊乱盛行率不断上升以及医疗基础设施不断完善,亚太地区综合代谢小组测试产业预计将在 2032 年之前以强劲速度扩张。人们对常规健康检查的偏好不断提高,诊断技术不断进步,将进一步推动区域市场的成长。
Comprehensive metabolic panel testing market size is projected to expand at 8.7% CAGR from 2023 to 2032, driven by the increasing prevalence of chronic diseases, rising aging population, and the greater need for early detection and monitoring of metabolic disorders.
The growing awareness of preventive healthcare and the increasing advancements in diagnostic technologies is driving the integration of comprehensive metabolic panels in routine health check-up. For instance, in January 2022, Quest Diagnostics introduced a Virtual Preventive Care Service via QuestDirect™ for empowering individuals to proactively manage their health and well-being. The surging demand for personalized medicine and the higher adoption of point-of-care testing will further amplify the market growth to meet the evolving healthcare needs of the diverse patient population.
The comprehensive metabolic panel testing industry is segregated into test type, disease indication, end-use, and region.
Based on test type, the market share from the kidney function tests segment is projected to exhibit 8.6% CAGR through 2032, attributed to the increasing prevalence of renal disorders. The rising aging population, and the critical role of kidney function tests in assessing and monitoring kidney health will boost the segment growth.
The liver disease indication segment is projected to capture sizeable share of the comprehensive metabolic panel testing market, recording 8.5% CAGR from 2023 to2032. The increasing prevalence of liver disorders is prompting the growing need for early detection. The crucial role of metabolic panels in assessing liver function will also fuel the segment expansion.
In terms of end-use, the market value form the hospitals segment is estimated to withhold 8.5% CAGR during 2023-2032. This is driven by the high patient volume in hospitals along with the growing need for rapid diagnostic services. Moreover, the routine incorporation of metabolic panels in comprehensive healthcare assessments will fuel the testing demand in hospital settings.
Regionally, the Asia Pacific comprehensive metabolic panel testing industry is slated to expand at robust rate through 2032, led by the increasing prevalence of metabolic disorders along with growing healthcare infrastructure. The rising preference for routine health check-ups and the increasing advancements in diagnostic technologies will further boost the regional market growth.